Call our 24 hours, seven days a week helpline at 800.272.3900

24/7 Helpline 800.272.3900
Donate

Alzheimer's Association Awards $4.3 Million to Accelerate Launch of New Drug Treatment Arms in Landmark Prevention Trial

Alzheimer's Association Awards $4.3 Million to Accelerate Launch of New Drug Treatment Arms in Landmark Prevention Trial
Share or Print this page
Share or Print this page
April 22, 2016
Email: media@alz.org
Share or Print this page

Alzheimer's Association Awards $4.3 Million to Accelerate Launch of New Drug Treatment Arms in Landmark Prevention Trial

The Alzheimer's Association announces a new $4.3 million research grant for a new phase of the Dominantly Inherited Alzheimer's Network Trials Unit (DIAN-TU) known as DIAN-TU Next Generation (NexGen). This award will accelerate the testing of new potential Alzheimer's therapies and a new diagnostic approach in people with genetically based, younger-onset Alzheimer's disease using an innovative trial design that is being applied to Alzheimer's for the first time.

About the Alzheimer's Association

The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900.

Keep Up With Alzheimer’s News and Events